Resumen de Investigación

Analyzed using Evidence Intelligence™

Liraglutide biosimilar shows significant weight reduction in T2DM patients

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 17 de julio de 2026

Key finding

Significant mean weight reduction of 5.5 ± 1.2 kg (7.3 ± 1.7%) was demonstrated by Liraglutide Biosimilar.

This Phase III trial compared Liraglutide Biosimilar with reference Liraglutide, finding both effective in reducing body weight and improving glycemic control.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

High Risk

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This Phase III trial compared Liraglutide Biosimilar with reference Liraglutide, finding both effective in reducing body weight and improving glycemic control.

Clinical relevance

These findings are clinically significant as they suggest that both Liraglutide Biosimilar and reference Liraglutide can effectively aid in weight management and glycemic control in patients with diabetes, potentially improving patient outcomes and quality of life.

Keep in mind

Unclear effectiveness for some outcomes. Limited generalizability due to specific population characteristics. Potential for unmeasured confounders affecting results.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Sujoy G, Bipin S, Sanjay K, et al. Phase III trial of Liraglutide Biosimilar in comparison with reference liraglutide. Cardiovascular diabetology. Endocrinology reports. 2025;11:6. doi:10.1186/s40842-025-00219-7

View DOI View on PubMed View on PMC

Efectos Principales

Liraglutide Biosimilar demonstrated a mean weight reduction of 5.5 kg (7.3%).

Reference Liraglutide showed a mean weight reduction of 7.1 kg (8.9%).

HbA1c improved significantly from 8.4% to 7.2% with Liraglutide Biosimilar.

HbA1c improved significantly from 8.6% to 7.1% with reference Liraglutide.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Liraglutide and Body weight, Fasting Plasma Glucose (FPG), Glucose iAUC (OGTT), and 1 more.

This study contributes evidence to

Intervention

Liraglutide

Outcome

Body weight

Evidence topic

Glycemic Control

Primary intervention

Liraglutide

Primary outcomes

Body weight
Fasting Plasma Glucose (FPG)
Glucose iAUC (OGTT)

Evidence topics

Glycemic Control HbA1c Reduction Weight Loss GLP-1 Receptor Agonists

Primary intervention

Liraglutide

Primary outcomes

Body weight Fasting Plasma Glucose (FPG)Glucose iAUC (OGTT)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 4 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and HbA1c

Evidencia relacionada

Relación de evidencia

GLP-1 Receptor Agonists and Body Weight

Guardar evidencia

Relación de evidencia

GLP-1 Receptor Agonists and Fasting Glucose

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Liraglutide → Body weight

Evidence Intelligence™

EvidenceScore™: 78; Strong
ImpactScore™: 88; Very Positive
ConsistencyScore™: 100; consistent

Basado en 4 estudios

Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Liraglutide → Fasting Plasma Glucose (FPG)

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Glucose iAUC (OGTT)

Liraglutide → Glucose iAUC (OGTT)

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 35; mixed

Basado en 2 estudios

Add to Evidence Tracker

HbA1c

Liraglutide → HbA1c

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Basado en 2 estudios

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

Liraglutide Biosimilar reduced body weight by 5.5 kg (p < 0.001).
Reference Liraglutide reduced body weight by 7.1 kg (p < 0.001).
Both treatments significantly improved HbA1c levels.

A quién se aplica

Adults with type 2 diabetes.
Individuals seeking weight management solutions.

Tener en Cuenta

Results may not apply to populations outside the study.
Further research needed to confirm long-term effectiveness.
Potential differences in response between individuals.

Entre Líneas

Unclear effectiveness for some outcomes.
Limited generalizability due to specific population characteristics.
Potential for unmeasured confounders affecting results.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Postprandial and OGTT Glucose.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: 78; Strong
ImpactScore™: 88; Very Positive
ConsistencyScore™: 100; consistent

Basado en 4 estudios

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Postprandial and OGTT Glucose

Medications

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 35; mixed

Basado en 2 estudios

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

Body Weight Evidence Hub

All studies measuring Body Weight

4 studies

outcome_hub

Measures Body Weight as a key outcome.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

4 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

Postprandial and OGTT Glucose Evidence Hub

All studies measuring Postprandial and OGTT Glucose

2 studies

outcome_hub

Measures Postprandial and OGTT Glucose as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Liraglutide and Body weight

Intervention: LiraglutideOutcome: Body weight

4 results

All studies on Liraglutide and Glucose iAUC (OGTT)

Intervention: LiraglutideOutcome: Glucose iAUC (OGTT)

2 results

All studies on Liraglutide

Intervention: Liraglutide

4 results

All studies measuring Body weight

Outcome: Body weight

4 results

All studies measuring Glucose iAUC (OGTT)

Outcome: Glucose iAUC (OGTT)

2 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists appears to improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 78.2 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve fasting glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve Fasting Glucose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 11 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve postprandial and ogtt glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve Postprandial and OGTT Glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Glucose iAUC (OGTT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Glycemic Control Evidence Hub HbA1c Reduction Evidence Hub Weight Loss Evidence Hub GLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Liraglutide and Body weight All studies on Liraglutide and Glucose iAUC (OGTT)All studies on Liraglutide and HbA1c All studies on Liraglutide and Fasting Plasma Glucose (FPG)

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patients HRS-7535 improves glycemic control in adults with type 2 diabetes Liraglutide 3 mg pathway improves weight loss.CT-868 Improves Glycaemic Control in Type 2 Diabetes

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.